Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

• DOI: 10.1007/s00408-024-00675-5
• Publication Date: 2024-03-13T20:57:50Z
• Authors: Davide Ramoni; Simona Coco; Giovanni Rossi; Chiara Dellepiane; Elisa Bennicelli; Sara Santamaria; Linda Zinoli; Alberto Stefano T...; Marco Tagliamento; Giulia Barletta; Luca Liberale; Amedeo Tirandi; Silvia Minetti; Maria Bertolotto; Fabrizio Montecucco; Carlo Genova; Federico Carbone
• Keywords: Osteopontin

Abstract Purpose Pembrolizumab-based regimens are conditioned by the expression of PD-L1, but durable response rate is limited innate and acquired resistance mechanisms. Here, we focus on osteopontin (OPN), an upfront biomarker senescence, which closely associated with natural history non-small cell lung cancer (NSCLC). Methods Seventy-nine patients eligible to pembrolizumab regimens—alone or in combination chemotherapy—as first-line treatment advanced NSCLC were enrolled. Predictive value OPN toward iRECIST progression disease (PD) was set as first outcome. Secondary ones included performance status (ECOG) at baseline, early (first best) responses, overall survival (OS). Results High Serum characterized worse ECOG-PS ( p = 0.015) baseline subjects experienced PD/death (OR 1.17 [1.02 1.35]; 0.030) best responses (0.04 [0.00 0.81]; 0.035). time-to-progression (B -2.74 [−4.46 −1.01]) time-to death (−0.13 [−0.20 −0.05]). Cox regression models unveil a predictive for iRECIST-PD (HR 1.01 [1.00 1.02]; −0.005), RECIST-PD 0.017), OS 1.02 [1.01 1.03]; 0.001). These internally validated through bootstrap resampling relevant discrimination ability ROC curve analyses. Conclusion Baseline levels serum short/long term outcomes NSCLC, candidate pembrolizumab-based regimens. As may pave way future studies focusing senescence patterns NSCLC.